Eisai Co. announced July 27 that its U.K. subsidiary, Eisai Europe Ltd., has received approval from the European Commission (EC) to market a new type of anti-epileptic drug. The drug perampanel, marketed as Fycompa, is the first in a new class of treatment for epilepsy to be approved by the EC. The drug works as an adjunctive, or add-on, treatment for partial-onset seizures in people with epilepsy aged 12 and older.
